Tag: adverum biotechnologies
June 10, 2019
Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022
Adverum Biotechnologies (NASDAQ:ADVM) has announced it has dosed the first patient in its second cohort of the ongoing OPTIC phase... May 16, 2019
Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022
Adverum Biotechnologies (NASDAQ:ADVM) has announced that the US Food and Drug Administration (FDA) has removed the clinical hold on the... February 11, 2019
Adverum Biotechnologies Announces Presentation of Preclinical Long-Term Safety Data of ADVM-022
Adverum Biotechnologies (NASDAQ:ADVM) has announced non-human private (NHP) long-term safety data of ADVM-022, gene therapy currently in phase 1 to...
December 4, 2018
5 Top NASDAQ Genetics Stocks Year-to-Date
As Q4 and 2018 come to a close, the Investing News Network profiles the five top genetics stocks on the... December 3, 2018
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the... November 19, 2018
Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022
Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced that...
October 4, 2018